View Older Stories View More Recent Stories

Aug 12, 2021 07:45AM Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board
Aug 12, 2021 07:45AM Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board
Jul 22, 2021 07:48AM Adagene Inc. (ADAG) Announces Clinical Trial Collaboration With Merck (MRK) to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs in Combination Therapy with KEYTRUDA
Jul 22, 2021 07:45AM Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)
Jul 22, 2021 07:45AM Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)
Jul 7, 2021 07:45AM Adagene Inc. (ADAG) Announces $20M Stock Buyback
Jul 7, 2021 07:45AM Adagene Announces Authorization of Share Repurchase Program up to US$20 Million
Jul 7, 2021 07:45AM Adagene Announces Authorization of Share Repurchase Program up to US$20 Million
Jun 16, 2021 07:45AM Adagene Announces Inclusion in FTSE Russell Indexes
Jun 16, 2021 07:45AM Adagene Announces Inclusion in FTSE Russell Indexes
May 25, 2021 04:05PM Adagene to Present at Upcoming Investor Conferences
May 25, 2021 04:05PM Adagene to Present at Upcoming Investor Conferences
May 19, 2021 05:10PM Adagene Inc. (ADAG) Presents Clinical Data from NEObody Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting
May 19, 2021 05:05PM Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting
May 19, 2021 05:05PM Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting
Mar 31, 2021 07:45AM Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates
Mar 31, 2021 07:45AM Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates
Mar 29, 2021 07:45AM Adagene Inc. (ADAG) Announces Clinical Advancement for ADG116
Mar 29, 2021 07:45AM Adagene Announces Clinical Advancement for ADG116
Mar 29, 2021 07:45AM Adagene Announces Clinical Advancement for ADG116
Mar 16, 2021 08:10AM Adagene Inc. (ADAG) Reports First Patients Dosed in Global Phase 1 Clinical Trial of ADG126
Mar 16, 2021 08:05AM Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program
Mar 16, 2021 08:05AM Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program
Feb 11, 2021 10:08AM Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option
Feb 11, 2021 10:08AM Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option
Feb 9, 2021 09:06AM Adagene Inc. (ADAG) Prices 7.35M ADS IPO at $19/ADS
Feb 9, 2021 09:00AM Adagene Inc. Announces Pricing of Initial Public Offering
Feb 9, 2021 09:00AM Adagene Inc. Announces Pricing of Initial Public Offering
View More Recent Stories View Older Stories